Eli Lilly bets $3.35B on a Chinese biotech's drug discovery platform #EliLilly #InnoCarePharma
Eli Lilly bets $3.35B on a Chinese biotech's drug discovery platform
Eli Lilly is partnering with Beijing-based InnoCare Pharma to develop drugs against up to five undisclosed targets — a deal potentially worth $3.35 billion. It's the latest in a string of massive bets by Lilly as it races to build out its pipeline beyond its blockbuster weight-loss drugs.
dlvr.it
September 24, 2026 at 5:35 PM
Eli Lilly bets $3.35B on a Chinese biotech's drug discovery platform #EliLilly #InnoCarePharma
#EliLilly has continued a busy period of #dealmaking with a wide-ranging #partnership with #China's #InnoCarePharma that includes upfront and near-term payments of $100 million.
pharmaphorum.com/news/lilly-f...
pharmaphorum.com/news/lilly-f...
Lilly forges $3.35bn alliance with China's InnoCare
Eli Lilly continues a busy period of deal-making with a five-project partnership with InnoCare that includes $100m in upfront and near-term payments.
pharmaphorum.com
September 24, 2026 at 11:05 AM
#EliLilly has continued a busy period of #dealmaking with a wide-ranging #partnership with #China's #InnoCarePharma that includes upfront and near-term payments of $100 million.
pharmaphorum.com/news/lilly-f...
pharmaphorum.com/news/lilly-f...